Immuno-Biological Laboratories Co., Ltd. (4570.T)
JPY 496.0
(-0.2%)
JPY 496.0
(-0.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -498.15 Million JPY | -31.38% |
| 2022 | -379.17 Million JPY | -38.21% |
| 2021 | -274.35 Million JPY | 46.64% |
| 2020 | -514.18 Million JPY | 31.17% |
| 2019 | -747 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -524 Million JPY | -5.19% |
| 2023 Q2 | -383.25 Million JPY | -3.23% |
| 2023 Q1 | -371.25 Million JPY | 2.09% |
| 2023 Q3 | -392.16 Million JPY | -2.33% |
| 2023 Q4 | -498.15 Million JPY | -27.03% |
| 2023 FY | -498.15 Million JPY | -31.38% |
| 2022 Q3 | -158 Million JPY | -52.21% |
| 2022 FY | -379.17 Million JPY | -38.21% |
| 2022 Q4 | -379.17 Million JPY | -139.98% |
| 2022 Q2 | -103.8 Million JPY | 0.0% |
| 2021 FY | -274.35 Million JPY | 46.64% |
| 2020 FY | -514.18 Million JPY | 31.17% |
| 2019 FY | - JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 167.068% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 56.069% |
| GNI Group Ltd. | -17.93 Billion JPY | 97.222% |
| Linical Co., Ltd. | -4.46 Billion JPY | 88.839% |
| Trans Genic Inc. | -221.16 Million JPY | -125.237% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 88.663% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 89.6% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 134.75% |
| AnGes, Inc. | -3.79 Billion JPY | 86.883% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -18.381% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 102.0% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -6.82% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 81.592% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 73.618% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | 49.279% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 85.336% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 51.848% |
| Kidswell Bio Corporation | 343.58 Million JPY | 244.985% |
| PeptiDream Inc. | 3.29 Billion JPY | 115.132% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | 48.781% |
| Ribomic Inc. | -2.09 Billion JPY | 76.275% |
| SanBio Company Limited | -3.78 Billion JPY | 86.855% |
| Healios K.K. | -2.19 Billion JPY | 77.253% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | 47.277% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 81.017% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 64.846% |
| StemRIM | -8.41 Billion JPY | 94.077% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 89.364% |
| FunPep Company Limited | -1.79 Billion JPY | 72.223% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 76.684% |
| Stella Pharma Corporation | -1.11 Billion JPY | 55.498% |
| TMS Co., Ltd. | -3.44 Billion JPY | 85.547% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 91.033% |
| Cuorips Inc. | -5.56 Billion JPY | 91.042% |
| K Pharma,Inc. | -3.26 Billion JPY | 84.749% |
| Takara Bio Inc. | -32.2 Billion JPY | 98.453% |
| ReproCELL Incorporated | -2.93 Billion JPY | 83.051% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | 24.632% |
| StemCell Institute Inc. | -2.83 Billion JPY | 82.439% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 75.892% |
| CellSeed Inc. | -2.01 Billion JPY | 75.241% |